APL-2301, a compound developed by Asieris for the treatment of Acinetobacter baumannii infection, was approved for Phase I clinical trials in Australia

UNLOCK DATA
Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech

Register Now

Want to read this important story?

Access thousands of news articles and data posts over the past 9 years!